神山　紀子Kohyama Noriko

Factors Associated With Sacubitril/Valsartan Continuation and the Methods of Combining Heart Failure Medications in Patients With Heart Failure, Iwasaki E, Kohyama N, Inamoto M, Nagao M, Sunaga T, Suzuki H, Ebato M, Kogo M, Annals of Pharmacotherapy, 2024年09月, 原著, 査読あり, DOI:doi.org/10.1177/10600280241277

Bleeding risk factors and real-world antithrombotic therapies in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention: a retrospective study, Kanako Fujita, Noriko Kohyama, Miki Sato, Tomokazu Deguchi, Hiroshi Suzuki, Mio Ebato, Mari Kogo, Journal of Pharmaceutical Health Care and Sciences, 9:41, 2023年12月, 原著, 査読あり, DOI:https://doi.org/10.1186/s40780-023-00308-8

Predictors of a Good Diuretic Response and Administration Methods for Carperitide in Patients With Acute Heart Failure, Inamoto M, Kohyama N, Suzuki H, Ebato M, Kogo M., Clinical Therapeutics, 46(1):12 - 19, 2023年11月, 原著, 査読あり, DOI:doi: 10.1016/j.clinthera.2023.10.006.

Population Pharmacokinetic Model and Dosing Simulation of Meropenem Using Measured Creatinine Clearance for Patients with Sepsis., Fukumoto Shiori;Ohbayashi Masayuki;Okada Akira;Kohyama Noriko;Tamatsukuri Tatsuro;Inoue Hideki;Kato Akihito;Kotani Toru;Sagara Hironori;Dohi Kenji;Kogo Mari, Therapeutic drug monitoring, 45(3):392 - 399, 2023年05月, 原著, 査読あり, DOI:10.1097/FTD.0000000000001040

Prognostic model for overall survival that includes the combination of platelet count and neutrophil-lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma., Miki Takenaka Sato, Ayuki Ida, Yuki Kanda, Kaori Takano, Masayuki Ohbayashi, Noriko Kohyama, Jun Morita, Kohzo Fuji, Haruaki Sasaki, Yoshio Ogawa, Mari Kogo., BMC Cancer, 2022年11月, 原著, 査読あり

Development of a model predicting cardiac events in heart failure patients with decreased renal function: a retrospective study, Deguchi Tomokazu;Sato Miki;Kohyama Noriko;Fujita Kanako;Nagumo Sakura;Suzuki Hiroshi;Ebato Mio;Kogo Mari, International Journal of Clinical Pharmacy, 45(1):210 - 219, 2022年11月, 原著, 査読あり, DOI:https://doi.org/10.1007/s11096-022-01502-8

Factors predicting addition of disease-modifying antirheumatic drugs after initial methotrexate monotherapy in patients with rheumatoid arthritis., YAMAGUCHI Takashi;KOHYAMA Noriko;TAKENAKA Miki;OKADA Takahiro;KURIHARA Tatsuya;SAKURAI Kosuke;MIWA Yusuke;KOGO Mari, Clin Rheumatol, 40(7):2657 - 2663, 2021年07月, 原著, 査読あり

Scoring Model to Predict a Low Disease Activity in Elderly Rheumatoid Arthritis Patients Initially Treated with Biological Disease-modifying Antirheumatic Drugs, OKADA Takahiro;KOHYAMA Noriko;TAKENAKA Miki;YAMAGUCHI Takashi;KURIHARA Tatsuya;SAKURAI Kosuke;MIWA Yusuke;KOGO Mari, Intern Med, 60(12):1827 - 1834, 2021年06月, 原著, 査読あり

Risk factors for initial antibiotic treatment failure in patients with aspiration pneumonia, FUKUDA Moemi;KOHYAMA Noriko;MAEDA Masayuki;KAWASAKI Tsutomu;YAMAMOTO Toshinori;KOGO Mari, Showa Univ J Med Sci, 33(2):55 - 64, 2021年06月, 原著, 査読あり

Rubric Assessment for Pharmacotherapy in Spiral Curriculum: Development and Usefulness Evaluation, HANDA Satoko;KOHYAMA Noriko;KURIHARA Tatsuya;SUGIYAMA Erika;TANAKA Sachiko;YAMAMOTO Hitomi;MIYASAKA Yoshiyuki;KOGO Mari;KATO Yasuhisa; NAKAMURA Akihiro;YAMAMOTO Toshinori, 薬学雑誌, 140(12):1441 - 1454, 2020年12月, 原著, 査読あり, DOI:10.1248/yakushi.20-00029

Finding prodromal frailty in a community-dwelling healthy older cohort by survey of BDNF or habd grip strength classified by BMI., HACHISU Mitsugu;HASHIZUME M;KAWAI H ;HIRANO H;KOJIMA M;FUJIWARA Y ;OBUCHI S;KOGO Mari;OHBAYASHI Masayuki;KOHYAMA Noriko;TAKENAKA Miki;IHARA K, Aging Pathobiol Ther, 2(3):155 - 161, 2020年07月, 原著, 査読あり

Factors associated with a reduction in the quality of life of patients with chronic hepatitis C treated by ledipasvir/sofosbuvir therapy, AIMONO Yuka;KOHYAMA Noriko;KAMOSHIDA Toshiro;YAMAMOTO Toshinori;KOGO Mari, Eur J Hosp Pharm, :2215, 2020年04月, 原著, 査読あり

Clinical Pharmacokinetics of Mianserin Suppositories in Healthy Older Japanese Male Adults: A Pilot Study, ICHIKUKRA Daisuke;NAWATA Shuichi;KOHYAMA Noriko;TOKUNAGA Megumi;HIDA Noriko;YAMAZAKI Taigi;TAKENOSHITA Sachiko;UCHIDA Naoki;MINEMURA Atsuko;SASAKI Tadanori, 臨床薬理, 50(2):23 - 30, 2019年03月, 原著, 査読あり

The exploration of population pharmacokinetic model for meropenem in augmented renal clearance and investigation of optimum setting of dose, TAMATSUKURI Tatsuro;OHBAYASHI Masayuki;KOHYAMA Noriko;KOBAYASHI Yasuna;YAMAMOTO Toshinori;FUKUDA Kenichiro;NAKAMURA Shunsuke;MIYAKE Yasufumi;DOHI Kenji;KOGO Mari, J Infect Chemother, 24(10):834 - 840, 2018年10月, 原著, 査読あり

Online Survey of Problems Inhibiting the Active Involvement of Community Pharmacists in Patients with Cancer Undergoing Outpatient Chemotherapy, KOBAYASHI Yasuna;SUGIHARA-TSUKUMOTO Keiko;KOBAYASHI Aya;KOHYAMA Noriko;YAMAMOTO Toshinori, J Academic Soc Qual Life, 3(2):1 - 9, 2017年06月, 原著, 査読あり

The Relationship between Internet-Use and Communication skills of students in a Japanese University, KOBAYASHI Yasuna;SUGIHARA-TSUKAMOTO Keiko;KOBAYASHI Aya;KOHYAMA Noriko;YAMAMOTO Toshinori, J Acad Soc Qual Life, 3(2):1 - 9, 2017年06月, 原著, 査読あり

The pharmacokinetics of mianserin suppositories for rectal administration in dogs and healthy volunteers: a pilot study, NAWATA Shuichi;KOHYAMA Noriko;UCHIDA Naoki;NUMAZAWA Satoshi;OHBAYASHI Masayuki;KOBAYASHI Yasuna;IWATA Masanori ;NAKAJIMA Takanori;SAITO Hiroshi;IZUKA Akira;YAMAMOTO Toshinori, J Pharm Health Care Sci, 2:12, 2016年06月, 原著, 査読あり

Effect of the GSTM1 Null Genotype on Glutathione S-Transferase (GST) Activity in Patients with Non-Viral Liver Tumors , FUJIMIYA Tatsuhiro;KOBAYASHI Yasuna;AOKI Takeshi;KOHYAMA Noriko;OHBAYASHI Masayuki;MURAKAMI Masahiko;YAMAMOTO Toshinori, Showa Univ J Med Sci, 28(2):113 - 121, 2016年06月, 原著, 査読あり, DOI:10.15369/sujms.28.113

Gene polymorphism and frequencies of the NPC1L1 gene (rs2072183, rs217434 and rs217428) in Japanese patients with dyslipidemia, KASHIWABARA Yuka;KOBAYASHI Yasuna; KOBA Shinji;KOHYAMA Noriko;OHBAYASHI Masayuki;MURAYAMA Junichiro;HIRANO Tsutomu;KOBAYASHI Youichi;YAMAMOTO Toshinori, J Clin Pharm Ther, 39(5):551 - 554, 2014年10月, 原著, 査読あり

Genetic polymorphism of the human organic solute carrier protein 1 (hOSCP1) gene in Japanese patients with non-viral liver carcinoma., TODA Mayumi;KOBAYASHI Yasuna;KOIZUMI Tomotake;SAITO Koji;OHBAYASHI Masayuki;KOHYAMA Noriko;AOKI Takeshi;MURAKAMI Masahiko;YASUHARA Hajime;YAMAMOTO Toshinori, Meta Gene, 2:686 - 693, 2014年10月, 原著, 査読あり

Involvement of epithelial-mesenchymal transition in methotrexate-induced pulmonary fibrosis., OHBAYASHI Masayuki;KUBOTA Satoshi;KAWASE Aya;KOHYAMA Noriko;KOBAYASHI Yasuna;YAMAMOTO Toshinori, J Toxicol Sci, 39(2):319 - 330, 2014年04月, 原著, 査読あり

Characterization of monocarboxylate transporter 6: expression in human intestine and transport of the antidiabetic drug nateglinide., Noriko Kohyama; Hisae Shiokawa; Masayuki Ohbayashi; Yasuna Kobayashi; Toshinori Yamamoto, Drug metabolism and disposition: the biological fate of chemicals, 41(11):1883 - 7, 2013年11月

Induction of pulmonary fibrosis by methotrexate treatment in mice lung in vivo and in vitro., OHBAYASHI Masayuki;SUZUKI Masanori;YASHIRO Yoshiki;FUKUWARA Sayaka;YASUDA Masako;KOHYAMA Noriko;KOBAYASHI Yasuna;YAMAMOTO Toshinori, J Toxicol Sci, 35(5):653 - 661, 2010年10月, 原著, 査読あり

Effect of interleukins response to ECM-induced acquisition of drug resistance in MCF-7 cells, M. Ohbayashi; M. Yasuda; I. Kawakami; N. Kohyama; Y. Kobayashi; T. Yamamoto, Experimental Oncology, 30(4):276 - 282, 2008年

Functional characterization of human monocarboxylate transporter 6 (SLC16A5), Y Murakami; N Kohyama; Y Kobayashi; M Ohbayashi; H Ohtani; Y Sawada; T Yamamoto, DRUG METABOLISM AND DISPOSITION, 33(12):1845 - 1851, 2005年12月